Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7176220 | GILEAD SCIENCES INC | 4-oxoquinoline compound and use thereof as pharmaceutical agent |
Aug, 2026
(3 years from now) | |
US8981103 | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Oct, 2026
(3 years from now) | |
US7635704 | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Oct, 2026
(3 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7176220
(Pediatric) | GILEAD SCIENCES INC | 4-oxoquinoline compound and use thereof as pharmaceutical agent |
Feb, 2027
(3 years from now) | |
US7635704
(Pediatric) | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Apr, 2027
(4 years from now) | |
US8981103
(Pediatric) | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Apr, 2027
(4 years from now) |
Market Authorisation Date: 24 September, 2014
Treatment: Treatment of hiv infection
Dosage: TABLET;ORAL
11
United States
8
Norway
8
Japan
8
European Union
4
Argentina
3
Peru
2
Portugal
2
Malaysia
2
Russia
2
Spain
2
Brazil
2
New Zealand
2
Mexico
2
China
2
Taiwan, Province of China
2
Korea, Republic of
2
Hong Kong
2
South Africa
2
Canada
2
Cyprus
2
Slovenia
2
Australia
2
Denmark
1
Turkey
1
Germany
1
Croatia
1
Austria
1
Slovakia
1
Lithuania
1
Luxembourg
1
Hungary
1
Czech Republic
1
Israel
1
Poland
1
RS
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic